NCT06393894Recruiting
Latvian Early Atherosclerosis Registry
A Prospective Registry to Assess Atherosclerosis Risk Factors and Their Relationship With Coronary Plaque Properties and Genetic Variations in Patients With Early Atherosclerosis of Unclear Origin.
Source: ClinicalTrials.gov · Last updated 1 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 15 Sept 2020
- Start date
- 1 Apr 2019
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Pauls Stradins Clinical University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06393894
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Apr 2019 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diabetes
Lab values
- Total cholesterol ≥7 mmol/l and/or LDL ≥ 5 mmol/l
Age
- positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \<55 years, women \<65 years)
- malignant or resistant hypertension ≥ 10 years
Other
- family hypercholesterolemia
- body mass index ≥40 kg/m 2 )
- 20 or more pack years of smoking
Who the study is looking for
- Signed informed consent
- Early atherosclerosis defined as coronary atherosclerosis in men aged \<55 years and women \<65 years
- Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia
- Coronary artery atherosclerosis with planned revascularization
- History of coronary artery revascularization (PTCA or coronary artery bypass surgery)
- Coronary vessel suitable for NIRS pullback
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pauls Stradins Clinical University Hospital Coordinator of this site? Confirm its status | Riga | Latvia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.